PMP22 and Charcot-Marie-Tooth disease type 1A: Ascorbic acid promotes myelination in vitro and possibly decreases PMP22 expression.2, 3 Evidence of efficacy of ascorbic acid in the animal model prompted initiation of randomised controlled trials to test the efficacy of ascorbic acid in patients with CMT1A.